Table 2 Clinical features, management and outcome of patients without GC therapy
Number | Gender | Involvement organ | Treatment regimen | Therapeutic response | Follow-up time (month) |
|---|---|---|---|---|---|
1 | M | Pancreas, Bile duct | Pancreatin Enteric-coated capsules | Non-remission | 22 |
2 | F | Pancreas, Submandibular gland, Lung | Hydroxychloroquine | Non-remission | 11 |
3 | M | Pancreas, Bile duct, Kidney, Submandibular gland | None | Non-remission | 43 |
4 | M | Submandibular gland, Pancreas, Lacrimal gland, Retroperitoneal fibrosis | None | Non-remission | 25 |
5 | M | Pancreas, Kidney | Pancreatin Enteric-coated capsules | Non-remission | 13 |
6 | M | Pancreas, Kidney, Lymph nodes | Tamoxifen | Non-remission | 18 |
7 | M | Pancreas, Bile duct | EMBE, UDCA | Non-remission | 3 |
8 | F | Pancreas | None | Non-remission | 9 |
9 | M | Pancreas, kidney | None | Non-remission | 17 |
10 | F | Pancreas, Bile duct | EMBE | Non-remission | 19 |
11 | M | Pancreas, Kidney | None | Remission | 3 |
12 | F | Pancreas | None | Remission | 15 |
13 | M | Pancreas, Bile duct | Pancreatin Enteric-coated capsules, UDCA | Remission | 61 |
14 | F | Pancreas, Bile duct | Pancreatin Enteric-coated capsules | Remission | 13 |
15 | M | Pancreas, Retroperitoneal fibrosis | None | Remission | 15 |
16 | F | Submandibular gland, Parotid gland | TwHF | Relapse | 33 |